Suppr超能文献

肝细胞癌患者肝移植米兰标准与加州大学旧金山分校标准的比较:一项系统评价和荟萃分析。

Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

作者信息

Bento de Sousa Jorge Henrique, Calil Igor Lepski, Tustumi Francisco, da Cunha Khalil Douglas, Felga Guilherme Eduardo Gonçalves, de Arruda Pecora Rafael Antonio, de Almeida Marcio Dias

机构信息

Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

University of São Paulo, Sao Paulo, Brazil.

出版信息

Transl Gastroenterol Hepatol. 2021 Jan 5;6:11. doi: 10.21037/tgh.2020.01.06. eCollection 2021.

Abstract

BACKGROUND

Liver transplantation is the main treatment for hepatocellular carcinoma (HCC). However, because of the limited supply of transplant organs, it is necessary to adopt a criterion that selects patients who will achieve adequate survival after transplantation. The aim of this review is to compare the two main staging criteria of HCC for the indication of liver transplantation (Milan and UCSF) and to analyze the post-transplantation survival rate at 1, 3 and 5 years.

METHODS

This is a systematic review and meta-analysis in which scientific articles from 5 databases (PubMed, Lilacs, Embase, Central, and Cinahl) were analyzed. The studies included in the review consisted of liver transplantation in patients with HCC in different subgroups according to donor type (deceased × living), population (eastern × western) and tumor evaluation (radiological × pathological) and adopted the Milan or UCSF criteria for the indication of the procedure.

RESULTS

There was no significant difference between the Milan and UCSF criteria in the overall survival rate at 1, 3 or 5 years, and the overall estimated value found was 1.03 [0.90, 1.17] at 1 year, 1.06 [0.96, 1.16] at 3 years and 1.04 [0.96, 1.12] at 5 years. Regarding the analysis of the subgroups, no significant difference was observed in any of the subgroups with a follow-up of 1, 3 or 5 years.

CONCLUSIONS

Both the Milan and UCSF criteria have equivalent survival rate. Thus, less restrictive method would not result in a great loss in the final overall survival rate and would benefit a greater number of patients.

摘要

背景

肝移植是肝细胞癌(HCC)的主要治疗方法。然而,由于移植器官供应有限,有必要采用一种标准来选择移植后能获得足够生存期的患者。本综述的目的是比较HCC用于肝移植指征的两种主要分期标准(米兰标准和加州大学旧金山分校标准),并分析1年、3年和5年的移植后生存率。

方法

这是一项系统综述和荟萃分析,其中分析了来自5个数据库(PubMed、Lilacs、Embase、Central和Cinahl)的科学文章。纳入综述的研究包括根据供体类型(已故×活体)、人群(东方×西方)和肿瘤评估(影像学×病理学)在不同亚组的HCC患者中进行的肝移植,并采用米兰或加州大学旧金山分校标准作为手术指征。

结果

米兰标准和加州大学旧金山分校标准在1年、3年或5年的总生存率上无显著差异,1年时的总体估计值为1.03[0.90,1.17],3年时为1.06[0.96,1.16],5年时为1.04[0.96,1.12]。关于亚组分析,在随访1年、3年或5年的任何亚组中均未观察到显著差异。

结论

米兰标准和加州大学旧金山分校标准的生存率相当。因此,限制较少的方法不会导致最终总生存率的大幅损失,且会使更多患者受益。

相似文献

引用本文的文献

9
Contemporary applications of Y90 for the treatment of hepatocellular carcinoma.Y90 在肝细胞癌治疗中的当代应用。
Hepatol Commun. 2023 Oct 2;7(10). doi: 10.1097/HC9.0000000000000288. eCollection 2023 Oct 1.

本文引用的文献

1
Liquid Biopsy: Current Status and Future Perspectives.液体活检:现状与未来展望。
Oncol Res Treat. 2017;40(7-8):404-408. doi: 10.1159/000478018. Epub 2017 Jul 13.
4
Immunological landscape and immunotherapy of hepatocellular carcinoma.肝细胞癌的免疫景观和免疫疗法。
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700. doi: 10.1038/nrgastro.2015.173. Epub 2015 Oct 20.
6
The evolving epidemiology of hepatocellular carcinoma: a global perspective.肝细胞癌不断演变的流行病学:全球视角
Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):765-79. doi: 10.1586/17474124.2015.1028363. Epub 2015 Apr 1.
9
Prognosis prediction and staging.预后预测与分期
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):855-65. doi: 10.1016/j.bpg.2014.08.002. Epub 2014 Aug 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验